Table 2 ATRX immunohistochemistry, alternative lengthening of telomeres, and their correlations in fusion-associated sarcomas, gastrointestinal stromal tumors, and epithelioid sarcomas
Sarcomas with fusion genes | N | ATRX loss | Alternative lengthening of telomeres (+) | Alternative lengthening of telomeres (−) | ||
|---|---|---|---|---|---|---|
N (%) | ATRX loss | N (%) | ATRX loss | |||
Mesenchymal chondrosarcoma | 3 | 0/3 (0%) | N/A | N/A | N/A | N/A |
Dermatofibrosarcoma protuberans | 10 | 0/10 (0%) | 0/9 (0%) | N/A | 9/9 (100%) | 0/9 (0%) |
Malignant solitary fibrous tumor | 7 | 0/7 (0%) | 0/7 (0%) | N/A | 7/7 (100%) | 0/7 (0%) |
Ewing sarcoma | 15 | 0/15 (0%) | 0/10 (0%) | N/A | 10/10 (100%) | 0/10 (0%) |
Alveolar rhabdomyosarcoma | 10 | 0/10 (0%) | 0/8 (0%) | N/A | 8/8 (100%) | 0/8 (0%) |
Synovial sarcoma | 18 | 0/18 (0%) | 0/13 (0%) | N/A | 13/13 (100%) | 0/13 (0%) |
Alveolar soft part sarcoma | 5 | 0/5 (0%) | 0/4 (0%) | N/A | 4/4 (100%) | 0/4 (0%) |
Extraskeletal myxoid chondrosarcoma | 3 | 0/3 (0%) | 0/2 (0%) | N/A | 2/2 (100%) | 0/2 (0%) |
Total | 71 | 0/71 (0%) | 0/53 (0%) | N/A | 53/53 (100%) | 0/53 (0%) |
Our previous studies a | ||||||
Myxoid liposarcoma | 20 | 0/20 (0%) | 1/19 (5%) | 0/1 (0%) | 18/19 (95%) | 0/18 (0%) |
Epithelioid hemangioendothelioma | 11 | 1/11 (9%) | 1/7 (14%) | 1/1 (100%) | 6/7 (86%) | 0/6 (0%) |
Total | 102 | 1/102 (1%) | 2/79 (3%) | 1/2 (50%) | 77/79 (97%) | 0/77 (0%) |
Others | ||||||
Gastrointestinal stromal tumor | 23 | 1/23 (4%) | 1/16 (6%) | 1/1 (100%) | 15/16 (94%) | 0/15 (0%) |
Epithelioid sarcoma | 10 | 0/10 (0%) | 0/6 (0%) | N/A | 6/6 (100%) | 0/6 (0%) |
